Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: There is controversy about the effects of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular disease (CVD) mortality. The aim of this study was to explore associations between NSAID use and mortality in patients with inflammatory polyarthritis (IP). SUBJECTS AND METHODS: A total of 923 patients with new onset (IP), recruited to the UK Norfolk Arthritis Register (NOAR) between 1990-1994, were followed up to the end of 2004. Current medication was recorded annually for the first 6 years and then every 2-3 years. Rheumatoid factor (RF) and C-reactive protein (CRP) were measured. Logistic regression was used to calculate all cause and CVD mortality odds ratios (OR) for NSAID use at baseline and during follow-up, adjusting for gender and time-varying covariates: RF, CRP, joint counts, smoking, steroid use, DMARD use and other medication use. RESULTS: By 2004 there were 203 deaths, 85 due to CVD. At baseline, NSAIDs were used by 66% of patients. In final multivariate models, baseline NSAID use was inversely associated with all cause mortality (adjusted OR 0.62, 95% CI 0.45 to 0.84) and CVD mortality (adjusted OR 0.54, 95% CI 0.34 to 0.86). Interval NSAID use had weaker mortality associations: all cause mortality (adjusted OR 0.72, 95% CI 0.52 to 1.00), CVD mortality (adjusted hazard ratio (HR) 0.66, 95% CI 0.40 to 1.08). CONCLUSION: No excess CVD or all cause mortality was observed in NSAID users in this cohort of patients with IP. This is at variance with the literature relating to NSAID use in the general population. It is unclear whether this represents unmeasured confounders influencing a doctor's decision to avoid NSAIDs in the treatment of IP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
Cited by
Peters, M. J. L., Symmons, D. P. M., McCarey, D., Dijkmans, B. A. C., Nicola, P., Kvien, T. K., McInnes, I. B., Haentzschel, H., Gonzalez-Gay, M. A., Provan, S., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.113696 · Cited by 1,325
Self-citationHarirforoosh, S., Asghar, W., & Jamali, F. (2014) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3vw2f · Cited by 960
Mason, J. C., & Libby, P. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu403 · Cited by 420
Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE
Symmons, D. P. M., & Gabriel, S. E. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.75 · Cited by 406
Self-citationAndrew, R., Derry, S., Taylor, R. S., Straube, S., & Phillips, C. J. (2014) · Pain Practice · doi:10.1111/papr.12050 · Cited by 375
Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives
Kitas, G. D., & Gabriel, S. E. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.142133 · Cited by 321
Increased mortality in ankylosing spondylitis is related to disease activity
Bakland, G., Gran, J. T., & Nossent, J. C. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.151191 · Cited by 294
Epidemiology of Rheumatoid Arthritis: Rheumatoid Arthritis and Mortality
Myasoedova, E., Davis, J. M., Crowson, C. S., & Gabriel, S. E. (2010) · Current Rheumatology Reports · doi:10.1007/s11926-010-0117-y · Cited by 188
“Some authors report no increased CV risk and even some beneficial effects on CV outcomes and all-cause mortality after treatment with NSAIDs [44].”
BackgroundMartín Arias, L. H., Martín González, A., Sanz Fadrique, R., & Vazquez, E. S. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1302 · Cited by 68
Metadata
- Authors
- Goodson, N. J., Brookhart, A. M., Symmons, D. P. M., Silman, A. J., & Solomon, D. H.
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2009-03
- Volume
- 68
- Issue
- 3
- Pages
- 367-372
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2130000778
- Cited by
- 93
- References
- 2
- FWCI
- 3.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.